Reset Map7 Results
204 SECOND AVE WALTHAM, Massachusetts, 02451-1126 United StatesKyinno Biotechnology is a preclinical contract research operation (CRO) dedicated to oncology drug discovery service and customized product development, with a focus on immuno-oncology and next-generation kinase inhibitor discovery. Our strength is the strong R&D team with decades of experience in the pharmaceutical and biotechnology industry in the United States. We have comprehensive development capability to construct stable cell lines engineered in unique and new targets through CRISPR Knock-in/Knock-out technology. Our animal facilities with a capacity of 1,000 cages (5,000 mice)are located in Beijing. We can perform 60 projects at the same time. Our service platforms include: 1. Off-the-shelf stable cell lines More than 3000 engineered cell lines are available (in stock) in our Waltham logistic center (MA, United States). The lead time will be 2~3 business days in the United States and about 2 weeks in Europe. 2. Custom cell line engineering Background cell lines. Over 700 human tumor cells and other animal cells are available for engineering. Technology. CRISPR Knock-in/Knock-out technology (homozygous clone and heterozygous clone) for site-specific integration. Overexpress gene/target using lentivirus vector transfection Standard deliver pool/single clone with validated PCR sequencing/Mycoplasma free/STR/HiBit test/Western Blot (WB) validation/siRNA test. 2. Cell-based assay validation and drug screening(small molecule compound and PROTACs) Cell proliferation assay(cell cytotoxicity assay).3D cell proliferation assay and 2D cell proliferation assay FACS binding assay/FACS internalization assay/ Immunol pathway assay/ ELISA assay ADCC cell-based bioassays/antibody-dependent cellular phagocytosis (ADCP) assays 3. Drug combination (in vivo combination and in vitro combination) integrated with bioinformatics analysis. 4. Pharmacology in vitro and in vivo study service, PK/PD efficacy studies in our ideal immunodeficient models. Hundreds of cell line-derived xenograft (CDX) mouse models are validated and are ready to test new anti-cancer drugs. BaF3 xenograft models Syngeneic models PBMC humanized mouse model Luciferase tumor model IVIS Imaging/Whole blood, spleen, and lymph node analysis/Chemotherapy validation 4. Phage display library and hybridoma technology for antibody drug discovery Humanization and affinity maturation Draggability and immunogenicity evaluation Nanobody Hybridoma services Single B cell sequencing 5. Common light chain technology 6. Cancer cell panel compound profiling and biomarker discovery 7. Mega screening platform HRD Homologous recombination deficiency (HRD) score of the cell lines was calculated and 100 cell lines with high HRD scores were selected for compound screening. Kinase BaF3 cell panel screening. With our gene-editing expertise, KYINNO has constructed over 700 BaF3 cell lines which harbor various hotspot kinase drug targets. Our dedicated cell-based assay team daily handles hundreds of BaF3 cell lines and thousands of test articles. Most of the engineered BaF3 cell lines are suitable for in vivo efficacy studies. By in vitro screening, the compounds showing good potency can be quickly selected for further in vivo efficacy study without any delay in our one-stop service. Target: EGFR family, VEGFR family, FGFR family, EML4, ALK, NTRK family, FLT3 family, ROS1, HER2, HER3, BCR-ABL, cKit, RET, TAM family, KRAS, NRAS, HRAS, IGF1R, TPR-Met, etc. Innovative membrane proteins screening array MPSA-AB5000 The specificity of antibodies, CAR-T cells, and other biologic therapeutics to their binding targets is an important step in the evaluation process of drug development. MPSA-AB5000 is a high-throughput cell-based platform for identifying the targets of antibodies and other ligands that bind to human membrane proteins for determining the specificity and preclinical safety of antibodies, CAR-T cell therapies, ADC, and other biotherapeutics. Here are some key features and benefits of AB5000: Unparalleled Antibody Specificity Screening. Our advanced platform allows for screening a wide range of human membrane proteins, which are critical for accurate specificity assessment. Early Off-Target Screening. The largest collection of human membrane proteins is natively expressed in live cells. You can conveniently determine the specificity and preclinical safety of biotherapeutics. Rapid, Simple, and Highly Sensitive. This cutting-edge technology provides rapid, simple, and highly sensitive results by measuring binding through ADCC via a luciferase reporter cell line. The wash-free strategy reduces false negatives, and signal amplification makes remarkable discrimination. Comprehensive Preclinical Safety Assessment. Our products catalogs: Kinase cell line Immune molecule cell line Gene Editing Cell line Engineered reporter cell lines Luciferase cell line Fluorescence-labeled cell line Drug-resistant cell line Antibody and proteins with fully validated functions in reporter cell lines Isotype control Therapeutic antibody Hybridoma Recombinant protein
3 Gil Street, suite G-100 Woburn, MA, 01801 United StatesKyinno Biotechnology is a preclinical contract research operation (CRO) dedicated to oncology drug discovery service and customized product development, with a focus on immuno-oncology and next-generation kinase inhibitor discovery. Our strength is the strong R&D team with decades of experience in the pharmaceutical and biotechnology industry in the United States. We have comprehensive development capability to construct stable cell lines engineered in unique and new targets through CRISPR Knock-in/Knock-out technology. Our animal facilities with a capacity of 1,000 cages (5,000 mice)are located in Beijing. We can perform 60 projects at the same time. Our service platforms include: 1. Off-the-shelf stable cell lines More than 3000 engineered cell lines are available (in stock) in our Waltham logistic center (MA, United States). The lead time will be 2~3 business days in the United States and about 2 weeks in Europe. 2. Custom cell line engineering Background cell lines. Over 700 human tumor cells and other animal cells are available for engineering. Technology. CRISPR Knock-in/Knock-out technology (homozygous clone and heterozygous clone) for site-specific integration. Overexpress gene/target using lentivirus vector transfection Standard deliver pool/single clone with validated PCR sequencing/Mycoplasma free/STR/HiBit test/Western Blot (WB) validation/siRNA test. 2. Cell-based assay validation and drug screening(small molecule compound and PROTACs) Cell proliferation assay(cell cytotoxicity assay).3D cell proliferation assay and 2D cell proliferation assay FACS binding assay/FACS internalization assay/ Immunol pathway assay/ ELISA assay ADCC cell-based bioassays/antibody-dependent cellular phagocytosis (ADCP) assays 3. Drug combination (in vivo combination and in vitro combination) integrated with bioinformatics analysis. 4. Pharmacology in vitro and in vivo study service, PK/PD efficacy studies in our ideal immunodeficient models. Hundreds of cell line-derived xenograft (CDX) mouse models are validated and are ready to test new anti-cancer drugs. BaF3 xenograft models Syngeneic models PBMC humanized mouse model Luciferase tumor model IVIS Imaging/Whole blood, spleen, and lymph node analysis/Chemotherapy validation 4. Phage display library and hybridoma technology for antibody drug discovery Humanization and affinity maturation Draggability and immunogenicity evaluation Nanobody Hybridoma services Single B cell sequencing 5. Common light chain technology 6. Cancer cell panel compound profiling and biomarker discovery 7. Mega screening platform HRD Homologous recombination deficiency (HRD) score of the cell lines was calculated and 100 cell lines with high HRD scores were selected for compound screening. Kinase BaF3 cell panel screening. With our gene-editing expertise, KYINNO has constructed over 700 BaF3 cell lines which harbor various hotspot kinase drug targets. Our dedicated cell-based assay team daily handles hundreds of BaF3 cell lines and thousands of test articles. Most of the engineered BaF3 cell lines are suitable for in vivo efficacy studies. By in vitro screening, the compounds showing good potency can be quickly selected for further in vivo efficacy study without any delay in our one-stop service. Target: EGFR family, VEGFR family, FGFR family, EML4, ALK, NTRK family, FLT3 family, ROS1, HER2, HER3, BCR-ABL, cKit, RET, TAM family, KRAS, NRAS, HRAS, IGF1R, TPR-Met, etc. Innovative membrane proteins screening array MPSA-AB5000 The specificity of antibodies, CAR-T cells, and other biologic therapeutics to their binding targets is an important step in the evaluation process of drug development. MPSA-AB5000 is a high-throughput cell-based platform for identifying the targets of antibodies and other ligands that bind to human membrane proteins for determining the specificity and preclinical safety of antibodies, CAR-T cell therapies, ADC, and other biotherapeutics. Here are some key features and benefits of AB5000: Unparalleled Antibody Specificity Screening. Our advanced platform allows for screening a wide range of human membrane proteins, which are critical for accurate specificity assessment. Early Off-Target Screening. The largest collection of human membrane proteins is natively expressed in live cells. You can conveniently determine the specificity and preclinical safety of biotherapeutics. Rapid, Simple, and Highly Sensitive. This cutting-edge technology provides rapid, simple, and highly sensitive results by measuring binding through ADCC via a luciferase reporter cell line. The wash-free strategy reduces false negatives, and signal amplification makes remarkable discrimination. Comprehensive Preclinical Safety Assessment. Our products catalogs: Kinase cell line Immune molecule cell line Gene Editing Cell line Engineered reporter cell lines Luciferase cell line Fluorescence-labeled cell line Drug-resistant cell line Antibody and proteins with fully validated functions in reporter cell lines Isotype control Therapeutic antibody Hybridoma Recombinant protein
204 Second Avenue Waltham, MA, 02451 United StatesKyinno Biotechnology is a preclinical contract research operation (CRO) dedicated to oncology drug discovery service and customized product development, with a focus on immuno-oncology and next-generation kinase inhibitor discovery. Our strength is the strong R&D team with decades of experience in the pharmaceutical and biotechnology industry in the United States. We have comprehensive development capability to construct stable cell lines engineered in unique and new targets through CRISPR Knock-in/Knock-out technology. Our animal facilities with a capacity of 1,000 cages (5,000 mice)are located in Beijing. We can perform 60 projects at the same time. Our service platforms include: 1. Off-the-shelf stable cell lines More than 3000 engineered cell lines are available (in stock) in our Waltham logistic center (MA, United States). The lead time will be 2~3 business days in the United States and about 2 weeks in Europe. 2. Custom cell line engineering Background cell lines. Over 700 human tumor cells and other animal cells are available for engineering. Technology. CRISPR Knock-in/Knock-out technology (homozygous clone and heterozygous clone) for site-specific integration. Overexpress gene/target using lentivirus vector transfection Standard deliver pool/single clone with validated PCR sequencing/Mycoplasma free/STR/HiBit test/Western Blot (WB) validation/siRNA test. 2. Cell-based assay validation and drug screening(small molecule compound and PROTACs) Cell proliferation assay(cell cytotoxicity assay).3D cell proliferation assay and 2D cell proliferation assay FACS binding assay/FACS internalization assay/ Immunol pathway assay/ ELISA assay ADCC cell-based bioassays/antibody-dependent cellular phagocytosis (ADCP) assays 3. Drug combination (in vivo combination and in vitro combination) integrated with bioinformatics analysis. 4. Pharmacology in vitro and in vivo study service, PK/PD efficacy studies in our ideal immunodeficient models. Hundreds of cell line-derived xenograft (CDX) mouse models are validated and are ready to test new anti-cancer drugs. BaF3 xenograft models Syngeneic models PBMC humanized mouse model Luciferase tumor model IVIS Imaging/Whole blood, spleen, and lymph node analysis/Chemotherapy validation 4. Phage display library and hybridoma technology for antibody drug discovery Humanization and affinity maturation Draggability and immunogenicity evaluation Nanobody Hybridoma services Single B cell sequencing 5. Common light chain technology 6. Cancer cell panel compound profiling and biomarker discovery 7. Mega screening platform HRD Homologous recombination deficiency (HRD) score of the cell lines was calculated and 100 cell lines with high HRD scores were selected for compound screening. Kinase BaF3 cell panel screening. With our gene-editing expertise, KYINNO has constructed over 700 BaF3 cell lines which harbor various hotspot kinase drug targets. Our dedicated cell-based assay team daily handles hundreds of BaF3 cell lines and thousands of test articles. Most of the engineered BaF3 cell lines are suitable for in vivo efficacy studies. By in vitro screening, the compounds showing good potency can be quickly selected for further in vivo efficacy study without any delay in our one-stop service. Target: EGFR family, VEGFR family, FGFR family, EML4, ALK, NTRK family, FLT3 family, ROS1, HER2, HER3, BCR-ABL, cKit, RET, TAM family, KRAS, NRAS, HRAS, IGF1R, TPR-Met, etc. Innovative membrane proteins screening array MPSA-AB5000 The specificity of antibodies, CAR-T cells, and other biologic therapeutics to their binding targets is an important step in the evaluation process of drug development. MPSA-AB5000 is a high-throughput cell-based platform for identifying the targets of antibodies and other ligands that bind to human membrane proteins for determining the specificity and preclinical safety of antibodies, CAR-T cell therapies, ADC, and other biotherapeutics. Here are some key features and benefits of AB5000: Unparalleled Antibody Specificity Screening. Our advanced platform allows for screening a wide range of human membrane proteins, which are critical for accurate specificity assessment. Early Off-Target Screening. The largest collection of human membrane proteins is natively expressed in live cells. You can conveniently determine the specificity and preclinical safety of biotherapeutics. Rapid, Simple, and Highly Sensitive. This cutting-edge technology provides rapid, simple, and highly sensitive results by measuring binding through ADCC via a luciferase reporter cell line. The wash-free strategy reduces false negatives, and signal amplification makes remarkable discrimination. Comprehensive Preclinical Safety Assessment. Our products catalogs: Kinase cell line Immune molecule cell line Gene Editing Cell line Engineered reporter cell lines Luciferase cell line Fluorescence-labeled cell line Drug-resistant cell line Antibody and proteins with fully validated functions in reporter cell lines Isotype control Therapeutic antibody Hybridoma Recombinant protein
204 Second Avenue Waltham, MA, 02451 United StatesKyinno Biotechnology is a preclinical contract research operation (CRO) dedicated to oncology drug discovery service and customized product development, with a focus on immuno-oncology and next-generation kinase inhibitor discovery. Our strength is the strong R&D team with decades of experience in the pharmaceutical and biotechnology industry in the United States. We have comprehensive development capability to construct stable cell lines engineered in unique and new targets through CRISPR Knock-in/Knock-out technology. Our animal facilities with a capacity of 1,000 cages (5,000 mice)are located in Beijing. We can perform 60 projects at the same time. Our service platforms include: 1. Off-the-shelf stable cell lines More than 3000 engineered cell lines are available (in stock) in our Waltham logistic center (MA, United States). The lead time will be 2~3 business days in the United States and about 2 weeks in Europe. 2. Custom cell line engineering Background cell lines. Over 700 human tumor cells and other animal cells are available for engineering. Technology. CRISPR Knock-in/Knock-out technology (homozygous clone and heterozygous clone) for site-specific integration. Overexpress gene/target using lentivirus vector transfection Standard deliver pool/single clone with validated PCR sequencing/Mycoplasma free/STR/HiBit test/Western Blot (WB) validation/siRNA test. 2. Cell-based assay validation and drug screening(small molecule compound and PROTACs) Cell proliferation assay(cell cytotoxicity assay).3D cell proliferation assay and 2D cell proliferation assay FACS binding assay/FACS internalization assay/ Immunol pathway assay/ ELISA assay ADCC cell-based bioassays/antibody-dependent cellular phagocytosis (ADCP) assays 3. Drug combination (in vivo combination and in vitro combination) integrated with bioinformatics analysis. 4. Pharmacology in vitro and in vivo study service, PK/PD efficacy studies in our ideal immunodeficient models. Hundreds of cell line-derived xenograft (CDX) mouse models are validated and are ready to test new anti-cancer drugs. BaF3 xenograft models Syngeneic models PBMC humanized mouse model Luciferase tumor model IVIS Imaging/Whole blood, spleen, and lymph node analysis/Chemotherapy validation 4. Phage display library and hybridoma technology for antibody drug discovery Humanization and affinity maturation Draggability and immunogenicity evaluation Nanobody Hybridoma services Single B cell sequencing 5. Common light chain technology 6. Cancer cell panel compound profiling and biomarker discovery 7. Mega screening platform HRD Homologous recombination deficiency (HRD) score of the cell lines was calculated and 100 cell lines with high HRD scores were selected for compound screening. Kinase BaF3 cell panel screening. With our gene-editing expertise, KYINNO has constructed over 700 BaF3 cell lines which harbor various hotspot kinase drug targets. Our dedicated cell-based assay team daily handles hundreds of BaF3 cell lines and thousands of test articles. Most of the engineered BaF3 cell lines are suitable for in vivo efficacy studies. By in vitro screening, the compounds showing good potency can be quickly selected for further in vivo efficacy study without any delay in our one-stop service. Target: EGFR family, VEGFR family, FGFR family, EML4, ALK, NTRK family, FLT3 family, ROS1, HER2, HER3, BCR-ABL, cKit, RET, TAM family, KRAS, NRAS, HRAS, IGF1R, TPR-Met, etc. Innovative membrane proteins screening array MPSA-AB5000 The specificity of antibodies, CAR-T cells, and other biologic therapeutics to their binding targets is an important step in the evaluation process of drug development. MPSA-AB5000 is a high-throughput cell-based platform for identifying the targets of antibodies and other ligands that bind to human membrane proteins for determining the specificity and preclinical safety of antibodies, CAR-T cell therapies, ADC, and other biotherapeutics. Here are some key features and benefits of AB5000: Unparalleled Antibody Specificity Screening. Our advanced platform allows for screening a wide range of human membrane proteins, which are critical for accurate specificity assessment. Early Off-Target Screening. The largest collection of human membrane proteins is natively expressed in live cells. You can conveniently determine the specificity and preclinical safety of biotherapeutics. Rapid, Simple, and Highly Sensitive. This cutting-edge technology provides rapid, simple, and highly sensitive results by measuring binding through ADCC via a luciferase reporter cell line. The wash-free strategy reduces false negatives, and signal amplification makes remarkable discrimination. Comprehensive Preclinical Safety Assessment. Our products catalogs: Kinase cell line Immune molecule cell line Gene Editing Cell line Engineered reporter cell lines Luciferase cell line Fluorescence-labeled cell line Drug-resistant cell line Antibody and proteins with fully validated functions in reporter cell lines Isotype control Therapeutic antibody Hybridoma Recombinant protein
Room 609, No.3 Building, Yizhuang Biomedical Garden, No. 88, Kechuang Six Street, Yizhuang Economic and Technological Development East Zone Beijing, Beijing, 101111 ChinaKyinno Biotechnology is a preclinical contract research operation (CRO) dedicated to oncology drug discovery service and customized product development, with a focus on immuno-oncology and next-generation kinase inhibitor discovery. Our strength is the strong R&D team with decades of experience in the pharmaceutical and biotechnology industry in the United States. We have comprehensive development capability to construct stable cell lines engineered in unique and new targets through CRISPR Knock-in/Knock-out technology. Our animal facilities with a capacity of 1,000 cages (5,000 mice)are located in Beijing. We can perform 60 projects at the same time. Our service platforms include: 1. Off-the-shelf stable cell lines More than 3000 engineered cell lines are available (in stock) in our Waltham logistic center (MA, United States). The lead time will be 2~3 business days in the United States and about 2 weeks in Europe. 2. Custom cell line engineering Background cell lines. Over 700 human tumor cells and other animal cells are available for engineering. Technology. CRISPR Knock-in/Knock-out technology (homozygous clone and heterozygous clone) for site-specific integration. Overexpress gene/target using lentivirus vector transfection Standard deliver pool/single clone with validated PCR sequencing/Mycoplasma free/STR/HiBit test/Western Blot (WB) validation/siRNA test. 2. Cell-based assay validation and drug screening(small molecule compound and PROTACs) Cell proliferation assay(cell cytotoxicity assay).3D cell proliferation assay and 2D cell proliferation assay FACS binding assay/FACS internalization assay/ Immunol pathway assay/ ELISA assay ADCC cell-based bioassays/antibody-dependent cellular phagocytosis (ADCP) assays 3. Drug combination (in vivo combination and in vitro combination) integrated with bioinformatics analysis. 4. Pharmacology in vitro and in vivo study service, PK/PD efficacy studies in our ideal immunodeficient models. Hundreds of cell line-derived xenograft (CDX) mouse models are validated and are ready to test new anti-cancer drugs. BaF3 xenograft models Syngeneic models PBMC humanized mouse model Luciferase tumor model IVIS Imaging/Whole blood, spleen, and lymph node analysis/Chemotherapy validation 4. Phage display library and hybridoma technology for antibody drug discovery Humanization and affinity maturation Draggability and immunogenicity evaluation Nanobody Hybridoma services Single B cell sequencing 5. Common light chain technology 6. Cancer cell panel compound profiling and biomarker discovery 7. Mega screening platform HRD Homologous recombination deficiency (HRD) score of the cell lines was calculated and 100 cell lines with high HRD scores were selected for compound screening. Kinase BaF3 cell panel screening. With our gene-editing expertise, KYINNO has constructed over 700 BaF3 cell lines which harbor various hotspot kinase drug targets. Our dedicated cell-based assay team daily handles hundreds of BaF3 cell lines and thousands of test articles. Most of the engineered BaF3 cell lines are suitable for in vivo efficacy studies. By in vitro screening, the compounds showing good potency can be quickly selected for further in vivo efficacy study without any delay in our one-stop service. Target: EGFR family, VEGFR family, FGFR family, EML4, ALK, NTRK family, FLT3 family, ROS1, HER2, HER3, BCR-ABL, cKit, RET, TAM family, KRAS, NRAS, HRAS, IGF1R, TPR-Met, etc. Innovative membrane proteins screening array MPSA-AB5000 The specificity of antibodies, CAR-T cells, and other biologic therapeutics to their binding targets is an important step in the evaluation process of drug development. MPSA-AB5000 is a high-throughput cell-based platform for identifying the targets of antibodies and other ligands that bind to human membrane proteins for determining the specificity and preclinical safety of antibodies, CAR-T cell therapies, ADC, and other biotherapeutics. Here are some key features and benefits of AB5000: Unparalleled Antibody Specificity Screening. Our advanced platform allows for screening a wide range of human membrane proteins, which are critical for accurate specificity assessment. Early Off-Target Screening. The largest collection of human membrane proteins is natively expressed in live cells. You can conveniently determine the specificity and preclinical safety of biotherapeutics. Rapid, Simple, and Highly Sensitive. This cutting-edge technology provides rapid, simple, and highly sensitive results by measuring binding through ADCC via a luciferase reporter cell line. The wash-free strategy reduces false negatives, and signal amplification makes remarkable discrimination. Comprehensive Preclinical Safety Assessment. Our products catalogs: Kinase cell line Immune molecule cell line Gene Editing Cell line Engineered reporter cell lines Luciferase cell line Fluorescence-labeled cell line Drug-resistant cell line Antibody and proteins with fully validated functions in reporter cell lines Isotype control Therapeutic antibody Hybridoma Recombinant protein
3 Gil Street, suite G-100 Woburn, MA, 01801 United StatesKyinno Biotechnology is a preclinical contract research operation (CRO) dedicated to oncology drug discovery service and customized product development, with a focus on immuno-oncology and next-generation kinase inhibitor discovery. Our strength is the strong R&D team with decades of experience in the pharmaceutical and biotechnology industry in the United States. We have comprehensive development capability to construct stable cell lines engineered in unique and new targets through CRISPR Knock-in/Knock-out technology. Our animal facilities with a capacity of 1,000 cages (5,000 mice)are located in Beijing. We can perform 60 projects at the same time. Our service platforms include: 1. Off-the-shelf stable cell lines More than 3000 engineered cell lines are available (in stock) in our Waltham logistic center (MA, United States). The lead time will be 2~3 business days in the United States and about 2 weeks in Europe. 2. Custom cell line engineering Background cell lines. Over 700 human tumor cells and other animal cells are available for engineering. Technology. CRISPR Knock-in/Knock-out technology (homozygous clone and heterozygous clone) for site-specific integration. Overexpress gene/target using lentivirus vector transfection Standard deliver pool/single clone with validated PCR sequencing/Mycoplasma free/STR/HiBit test/Western Blot (WB) validation/siRNA test. 2. Cell-based assay validation and drug screening(small molecule compound and PROTACs) Cell proliferation assay(cell cytotoxicity assay).3D cell proliferation assay and 2D cell proliferation assay FACS binding assay/FACS internalization assay/ Immunol pathway assay/ ELISA assay ADCC cell-based bioassays/antibody-dependent cellular phagocytosis (ADCP) assays 3. Drug combination (in vivo combination and in vitro combination) integrated with bioinformatics analysis. 4. Pharmacology in vitro and in vivo study service, PK/PD efficacy studies in our ideal immunodeficient models. Hundreds of cell line-derived xenograft (CDX) mouse models are validated and are ready to test new anti-cancer drugs. BaF3 xenograft models Syngeneic models PBMC humanized mouse model Luciferase tumor model IVIS Imaging/Whole blood, spleen, and lymph node analysis/Chemotherapy validation 4. Phage display library and hybridoma technology for antibody drug discovery Humanization and affinity maturation Draggability and immunogenicity evaluation Nanobody Hybridoma services Single B cell sequencing 5. Common light chain technology 6. Cancer cell panel compound profiling and biomarker discovery 7. Mega screening platform HRD Homologous recombination deficiency (HRD) score of the cell lines was calculated and 100 cell lines with high HRD scores were selected for compound screening. Kinase BaF3 cell panel screening. With our gene-editing expertise, KYINNO has constructed over 700 BaF3 cell lines which harbor various hotspot kinase drug targets. Our dedicated cell-based assay team daily handles hundreds of BaF3 cell lines and thousands of test articles. Most of the engineered BaF3 cell lines are suitable for in vivo efficacy studies. By in vitro screening, the compounds showing good potency can be quickly selected for further in vivo efficacy study without any delay in our one-stop service. Target: EGFR family, VEGFR family, FGFR family, EML4, ALK, NTRK family, FLT3 family, ROS1, HER2, HER3, BCR-ABL, cKit, RET, TAM family, KRAS, NRAS, HRAS, IGF1R, TPR-Met, etc. Innovative membrane proteins screening array MPSA-AB5000 The specificity of antibodies, CAR-T cells, and other biologic therapeutics to their binding targets is an important step in the evaluation process of drug development. MPSA-AB5000 is a high-throughput cell-based platform for identifying the targets of antibodies and other ligands that bind to human membrane proteins for determining the specificity and preclinical safety of antibodies, CAR-T cell therapies, ADC, and other biotherapeutics. Here are some key features and benefits of AB5000: Unparalleled Antibody Specificity Screening. Our advanced platform allows for screening a wide range of human membrane proteins, which are critical for accurate specificity assessment. Early Off-Target Screening. The largest collection of human membrane proteins is natively expressed in live cells. You can conveniently determine the specificity and preclinical safety of biotherapeutics. Rapid, Simple, and Highly Sensitive. This cutting-edge technology provides rapid, simple, and highly sensitive results by measuring binding through ADCC via a luciferase reporter cell line. The wash-free strategy reduces false negatives, and signal amplification makes remarkable discrimination. Comprehensive Preclinical Safety Assessment. Our products catalogs: Kinase cell line Immune molecule cell line Gene Editing Cell line Engineered reporter cell lines Luciferase cell line Fluorescence-labeled cell line Drug-resistant cell line Antibody and proteins with fully validated functions in reporter cell lines Isotype control Therapeutic antibody Hybridoma Recombinant protein
204 SECOND AVE WALTHAM, MA, 02451-1126 United StatesKyinno Biotechnology is a preclinical contract research operation (CRO) dedicated to oncology drug discovery service and customized product development, with a focus on immuno-oncology and next-generation kinase inhibitor discovery. Our strength is the strong R&D team with decades of experience in the pharmaceutical and biotechnology industry in the United States. We have comprehensive development capability to construct stable cell lines engineered in unique and new targets through CRISPR Knock-in/Knock-out technology. Our animal facilities with a capacity of 1,000 cages (5,000 mice)are located in Beijing. We can perform 60 projects at the same time. Our service platforms include: 1. Off-the-shelf stable cell lines More than 3000 engineered cell lines are available (in stock) in our Waltham logistic center (MA, United States). The lead time will be 2~3 business days in the United States and about 2 weeks in Europe. 2. Custom cell line engineering Background cell lines. Over 700 human tumor cells and other animal cells are available for engineering. Technology. CRISPR Knock-in/Knock-out technology (homozygous clone and heterozygous clone) for site-specific integration. Overexpress gene/target using lentivirus vector transfection Standard deliver pool/single clone with validated PCR sequencing/Mycoplasma free/STR/HiBit test/Western Blot (WB) validation/siRNA test. 2. Cell-based assay validation and drug screening(small molecule compound and PROTACs) Cell proliferation assay(cell cytotoxicity assay).3D cell proliferation assay and 2D cell proliferation assay FACS binding assay/FACS internalization assay/ Immunol pathway assay/ ELISA assay ADCC cell-based bioassays/antibody-dependent cellular phagocytosis (ADCP) assays 3. Drug combination (in vivo combination and in vitro combination) integrated with bioinformatics analysis. 4. Pharmacology in vitro and in vivo study service, PK/PD efficacy studies in our ideal immunodeficient models. Hundreds of cell line-derived xenograft (CDX) mouse models are validated and are ready to test new anti-cancer drugs. BaF3 xenograft models Syngeneic models PBMC humanized mouse model Luciferase tumor model IVIS Imaging/Whole blood, spleen, and lymph node analysis/Chemotherapy validation 4. Phage display library and hybridoma technology for antibody drug discovery Humanization and affinity maturation Draggability and immunogenicity evaluation Nanobody Hybridoma services Single B cell sequencing 5. Common light chain technology 6. Cancer cell panel compound profiling and biomarker discovery 7. Mega screening platform HRD Homologous recombination deficiency (HRD) score of the cell lines was calculated and 100 cell lines with high HRD scores were selected for compound screening. Kinase BaF3 cell panel screening. With our gene-editing expertise, KYINNO has constructed over 700 BaF3 cell lines which harbor various hotspot kinase drug targets. Our dedicated cell-based assay team daily handles hundreds of BaF3 cell lines and thousands of test articles. Most of the engineered BaF3 cell lines are suitable for in vivo efficacy studies. By in vitro screening, the compounds showing good potency can be quickly selected for further in vivo efficacy study without any delay in our one-stop service. Target: EGFR family, VEGFR family, FGFR family, EML4, ALK, NTRK family, FLT3 family, ROS1, HER2, HER3, BCR-ABL, cKit, RET, TAM family, KRAS, NRAS, HRAS, IGF1R, TPR-Met, etc. Innovative membrane proteins screening array MPSA-AB5000 The specificity of antibodies, CAR-T cells, and other biologic therapeutics to their binding targets is an important step in the evaluation process of drug development. MPSA-AB5000 is a high-throughput cell-based platform for identifying the targets of antibodies and other ligands that bind to human membrane proteins for determining the specificity and preclinical safety of antibodies, CAR-T cell therapies, ADC, and other biotherapeutics. Here are some key features and benefits of AB5000: Unparalleled Antibody Specificity Screening. Our advanced platform allows for screening a wide range of human membrane proteins, which are critical for accurate specificity assessment. Early Off-Target Screening. The largest collection of human membrane proteins is natively expressed in live cells. You can conveniently determine the specificity and preclinical safety of biotherapeutics. Rapid, Simple, and Highly Sensitive. This cutting-edge technology provides rapid, simple, and highly sensitive results by measuring binding through ADCC via a luciferase reporter cell line. The wash-free strategy reduces false negatives, and signal amplification makes remarkable discrimination. Comprehensive Preclinical Safety Assessment. Our products catalogs: Kinase cell line Immune molecule cell line Gene Editing Cell line Engineered reporter cell lines Luciferase cell line Fluorescence-labeled cell line Drug-resistant cell line Antibody and proteins with fully validated functions in reporter cell lines Isotype control Therapeutic antibody Hybridoma Recombinant protein
Site Information
The Contract Research Map is owned and maintained by Scientist.com. It was created to help researchers in the life sciences identify and connect with contract research organizations (CROs) based on geography. Updated nightly, this map features all of the available CROs within our network, so you can order services with a few clicks. Click on a specific country, scroll on the map itself or type into the search bar at the top—there are many ways to find the location and suppliers that you’re looking for. From Argentina to New Zealand, use this map to connect with a CRO near you.
We believe that every researcher across the world should be able to connect with the thousands of global CROs that exist and have the opportunity to work together. Like many industries,the life science supply chain has been disrupted over the last year. But there are many other circumstances such as international customs regulations or sensitive shipping times that create limitations around which countries are feasible to partner with. Sometimes, finding a CRO based in a country that best suits your research needs is imperative. We hope this contract research map allows you to find the right partner in the right place at the right time.
Have questions or feedback? We’d love to help. You can find our FAQs and contact information on the Learn more page.
Interested in connecting with one or more of the contract research organizations listed on this map? By clicking on the company’s name, you will be directed to their supplier profile on the Scientist.com marketplace. Once you set up a marketplace account you can start the ordering process immediately.
What is Scientist.com?
Scientist.com is the world's largest enterprise marketplace for outsourced R&D services. It saves time and money and provides access to innovation while maintaining compliance with an organization’s procurement policies.
How can I use Scientist.com?
Scientist.com has built private, enterprise marketplaces from 24 of the 30 largest pharmaceutical companies, 80+ biotech companies, the US National Institutes of Health (NIH) and numerous other pharma and biotech companies. If you are employed by one of these organizations, you can log in to get started today. If you are unsure about how to get started, you can email our team at support@scientist.com or go to our website www.scientist.comto speak to someone via our live chat.
Why should I place my order through Scientist.com?
Scientist.com is a highly efficient enterprise-wide outsourcing marketplace that makes it possible for research organizations to save time and money, access innovation and ensure compliance. It utilizes a universal legal agreement and AI technologies to enable research like never before. See how comparing proposals and getting 1-on-1 support from our Research Concierge® team will enable you to place more research today.
How do I get my organization listed on the map?
If your CRO isn’t showing up on the map, then please be sure your company profile is up to date in Scientist.com’s Backoffice. After logging in, click the Your Company button in the navigation at the top, and then select the Locations tab.
Information about my organization is incorrect, how do I fix it?
Head over to backoffice.scientist.com to update your supplier profile and information. It may take up to two business days for the updates to be reflected on the map.